ESR1 and cancer: Moreover, fulvestrant, a selective ER degrader, has shown clinical benefits in patients whose cancers have relapsed on tamoxifen, indicating that ERα might continue to play important roles in tamoxifen-resistant breast cancer growth [10–12].